Do we have any leverage against drug-resistant organisms? Dr Maciej Boni explains the biological fitness cost of drug resistance and the worrisome scenarios that could develop if we lose this small advantage in our fight against drug-resistant pathogens. Dr Boni is a Wellcome Trust
Royal Society Sir Henry Dale Fellow leading a research programme on the epidemiology and evolution of influenza in the tropics. Parts of his doctoral and postdoctoral work focused on developing public health strategies aimed at rolling back drug resistance.
Can we eliminate drug resistance?
In some areas of global health we have made great strides over the past decade. Although much remains to be done, great progress has been made in the fields of malaria, HIV, the neglected tropical diseases, tuberculosis and many other infections. Maternal and child health have been improving, and funding for global health programmes has increased significantly. But the rise of…